These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8737198)

  • 1. Benefit and costs of anti-hypertensive treatment.
    Mancia G; Giannattasio C
    Eur Heart J; 1996 Mar; 17 Suppl A():25-8. PubMed ID: 8737198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
    Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
    J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension--when is the clinical problem solved? When patients are rendered normotensive.
    Mancia G; Lanfranchi A; Cattaneo BM; Grassi G
    Cardiology; 1994; 85 Suppl 1():58-64. PubMed ID: 7743536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension and coronary heart disease risk factor management.
    Houston MC
    Aust Fam Physician; 1994 Feb; 23(2):243-5, 248-51. PubMed ID: 8161313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the management of hypertension at primary health care level. Hypertension Society of Southern Africa, endorsed by the Medical Association of South Africa and the Medical Research Council.
    S Afr Med J; 1995 Dec; 85(12 Pt 2):1321-5. PubMed ID: 8600604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.
    Hermida RC; Ayala DE; Smolensky MH; Fernández JR; Mojón A; Portaluppi F
    Hypertens Res; 2016 May; 39(5):277-92. PubMed ID: 26657008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic impact of hypertension.
    Elliott WJ
    J Clin Hypertens (Greenwich); 2003; 5(3 Suppl 2):3-13. PubMed ID: 12826765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
    Kirchengast M
    J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences from hypertension trials. Impact of other risk factors.
    Samuelsson O
    Drugs; 1988; 36 Suppl 3():9-20. PubMed ID: 3076127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertension as a function of age].
    Gensini GF; Corradi F
    Ital Heart J; 2000 Jun; 1 Suppl 2():23-31. PubMed ID: 10905125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure variability: clinical implications and effects of antihypertensive treatment.
    Parati G; Ravogli A; Frattola A; Groppelli A; Ulian L; Santucciu C; Mancia G
    J Hypertens Suppl; 1994 Jul; 12(5):S35-40. PubMed ID: 7965285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of health outcome and associated costs in cardiovascular disease.
    Jönsson B
    Eur Heart J; 1996 Mar; 17 Suppl A():2-7. PubMed ID: 8737194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.